InterLeukin Combinatorial Therapies

InterLeukin Combinatorial Therapies (ILCT) was a biotechnology company focused on developing next-generation cytokine therapies for cancer and infectious diseases. The company's core technology involved the engineering of combinatorial interleukin variants designed to optimize immune system activation while minimizing systemic toxicity. By leveraging structural biology and protein engineering, ILCT aimed to create potent, targeted immunotherapies that could be used as monotherapies or in combination with checkpoint inhibitors. Although the company made strides in pre-clinical validation of its cytokine candidates, it is no longer actively operating as an independent entity.